Repligen posted solid growth and beat Wall Street's sales and adjusted earnings estimates.

Emanuel hasn’t published an estimate for aggregate EPS for 2026, but he sees plenty of reason profits can continue to ...

Entergy has strong growth potential but appears overvalued. See why ETR stock’s favorable regulatory environment and dividend ...

Earnings per share (EPS) rose to Tk50.11, up from Tk40.86 in FY23. According to its reports, at the end of June 2024, it owns Tk1,212 crore short-term investment as fixed deposits receipt (FDR) in ...

The meat industry powerhouse reported a strong bottom-line recovery, with profitability rebounding in key segments.

Over the last four quarters, the company has surpassed consensus EPS estimates just once. Kopin , which belongs to the Zacks Electronics - Miscellaneous Products industry, posted revenues of $13.32 ...

Nice NICE is set to release third-quarter 2024 results on Nov. 14. For the to-be-reported quarter, NICE expects non-GAAP ...

EBIT of $336M was down 46% YoY Net income of $310M was down 43% YoY Diluted EPS of $0.24 were down 40% YoY The gross profit ...

Reports Q3 revenue $13.6B, consensus $13.09B. Pascal Soriot, CEO, AstraZeneca (AZN), commenting on the results said: “Our company has ...

So if you're searching for promising tech stocks that might mint new millionaires in a few years, you should look among the ...

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of ...